• Home
  • NEW DAY MEDICINE
  • 2 (30) 2020
  • 172 -2 (30/4) 2020 — Khamzayev K.A., Sharipov A.M., — EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN TREATMENT OF STEROID-RESISTANT NEPHROTIC SYNDROME IN CHILDREN

172 -2 (30/4) 2020 — Khamzayev K.A., Sharipov A.M., — EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN TREATMENT OF STEROID-RESISTANT NEPHROTIC SYNDROME IN CHILDREN

EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN TREATMENT OF STEROID-RESISTANT NEPHROTIC SYNDROME IN CHILDREN

Khamzayev K.A., -Tashkent Pediatric Medical Institute. 223, Bagishamal Street, Tashkent, 100140. http://tashpmi.uz.

Sharipov A.M., -Tashkent Pediatric Medical Institute. 223, Bagishamal Street, Tashkent, 100140. http://tashpmi.uz.

Shoikromov Sh.Sh. -Tashkent Pediatric Medical Institute. 223, Bagishamal Street, Tashkent, 100140. http://tashpmi.uz.

Resume,

Effectiveness of methylprednisolone and cyclophosphamide pulse therapy in children with steroid-resistant nephrotic syndrome (SRNS) were studied. This method was used to treat 34 children with SRNS. Among patients with primary nephrotic syndrome, there was a higher incidence of steroid-resistant nephrotic syndrome (27.8%). The use of methylprednisolone and cyclophosphamide pulse therapy has a positive effect in 47 % of patients with steroid-resistant nephrotic syndrome with morphological types such as minimal change disease and membranous nephritis. Revealed low efficiency of methylprednisolone and cyclophosphamide pulse therapy in the treatment of focal-segmental glomerulosclerosis in children.

Key words: Cyclophosphamide efficacy in the treatment of steroid-resistant nephrotic syndrome in children.

First page

646

Last page

659

For citation: Khamzayev K.A., Sharipov A.M., Shoikromov Sh.Sh., Effectiveness of cyclophosphamide in treatment of steroid-resistant nephrotic syndrome in children//New Day in Medicine 2(30)2020 646-659 https://cutt.ly/WvDoWt8

List of References

  1. Lombel RM, Gipson DS, Hodson EM. Treatment of steroid­sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 415—26.
  2. Nourbakhsh N, Mak RH. Steroid-resistant nephrotic syndrome: past and current perspectives. Pediatric Health Med Ther 2017; 8: 29—37.
  3. Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid- resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015; 10: 592— 600.
  4. Deschenes G, Vivarelli M, Peruzzi L. Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 2017; 176: 647—54.
  5. Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid- resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015; 10: 592— 600.
  6. Gi pson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80: 868—78.
  7. Trautmann A, Schnaidt S, Lipska-Zietkiewicz BS, et al. Long­term outcome of steroid-resistant nephrotic syndrome in children. J Am Soc Nephrol 2017; 28: 3055—65.
  8. Rheault MN, Zhang L, Selewski DT, et al. AKI in children hospitalized with nephrotic syndrome. Clin J Am Soc Nephrol 2015; 10: 2110—18.
  9. Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8: 824—32.
  10. Sinha A, Gupta A, Kalaivani M, Hari P, Dinda AK, Bagga A. Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 2017; 92: 248—57.
  11. Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012; 82: 1130—35.
  12. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010; 10: CD003594.
  13. McCaffrey J, Lennon R, Webb NJ. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol 2016; 31: 1383—402.
  14. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360.
  15. Latta K, Von SC, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16: 271—82.
  16. Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int 2017; 91: 937—47.
  17. Dogra S, Kaskel F. Steroid-resistant nephrotic syndrome: a persistent challenge for pediatric nephrology. Pediatr Nephrol 2017; 32: 965—74.
  18. McCaffrey J, Lennon R, Webb NJ. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol 2016; 31: 1383—402.

file

download